PACE GARY W
Known title: DirectorCIK: 0001184778
PACE GARY W's purchase track record
How the stock did after each of PACE GARY W's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
6
of 8 since September 21, 2021
Stock higher 6 months later
67%
3 months: 50%
Median 6-month return
+5.3%
3 months: -1.3%
Beat the S&P 500
67%
median +5.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/14/2026 | CRDF | $1000K | -22.9% | pending | — |
| 6/18/2026 | CRDF | $37K | +7.4% | pending | — |
| 7/30/2025 | CRDF | $711K | -10.0% | -34.9% | +9.7% |
| 12/11/2024 | CRDF | $940K | +12.2% | +4.6% | -1.0% |
| 12/19/2023 | CRDF | $41K | +258.1% | +83.8% | +15.1% |
| 11/10/2023 | CRDF | $22K | +81.0% | +239.0% | +18.3% |
| 9/15/2022 | CRDF | $257K | -16.2% | +6.0% | +1.5% |
| 9/21/2021 | CRDF | $203K | -10.8% | -61.8% | +3.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CRDF | ▲ Buy | Open Market | 687,285 | $1000K | 7/14/2026 | View on chart |
| CRDF | ▲ Buy | Open Market | 30,000 | $37K | 6/18/2026 | View on chart |
| CRDF | ▲ Buy | Open Market | 275,000 | $674K | 7/30/2025 | View on chart |
| CRDF | ▲ Buy | Open Market | 15,000 | $37K | 7/30/2025 | View on chart |
| CRDF | ▲ Buy | Open Market | 350,115 | $910K | 12/11/2024 | View on chart |
| CRDF | ▲ Buy | Open Market | 11,500 | $30K | 12/11/2024 | View on chart |
| PCRX | ▼ Sell | Open Market | 90,000 | $2.8M | 3/8/2024 | View on chart |
| PCRX | ▼ Sell | Open Market | 28,257 | $871K | 3/7/2024 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,066 | $32K | 3/6/2024 | View on chart |
| CRDF | ▲ Buy | Open Market | 30,000 | $41K | 12/19/2023 | View on chart |
| CRDF | ▲ Buy | Open Market | 22,950 | $22K | 11/10/2023 | View on chart |
| PCRX | ▲ Buy | Grant | 1,775 | $0 | 6/14/2023 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 7,000 | $209K | 5/11/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 5,015 | $210K | 5/11/2023 | View on chart |
| CRDF | ▲ Buy | Open Market | 150,000 | $257K | 9/15/2022 | View on chart |
| PCRX | ▲ Buy | Grant | 1,160 | $0 | 6/8/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 7,000 | $76K | 3/3/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 1,166 | $13K | 3/1/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 193 | $2K | 3/1/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,359 | $92K | 3/1/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 9,807 | $108K | 2/28/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 18,834 | $208K | 2/28/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 28,641 | $1.9M | 2/28/2022 | View on chart |
| CRDF | ▲ Buy | Open Market | 30,000 | $203K | 9/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.